ErbB2 amplification and overexpression in breast cancer correlates with aggressive disease and poor prognosis. To find novel ErbB2-interacting proteins, we used stable isotope labeling of amino acids in cell culture followed by peptide affinity pull-downs and identified specific binders using relative quantification by mass spectrometry. Copine-III, a member of a Ca 2 þ -dependent phospholipid-binding protein family, was identified as binding to phosphorylated Tyr1248 of ErbB2. In breast cancer cells, Copine-III requires Ca 2 þ for binding to the plasma membrane, where it interacts with ErbB2 upon receptor stimulation, an interaction that is dependent on receptor activity. Copine-III also binds receptor of activated C kinase 1 and colocalizes with phosphorylated focal adhesion kinase at the leading edge of migrating cells. Importantly, knockdown of Copine-III in T47D breast cancer cells causes a decrease in Src kinase activation and ErbB2-dependent wound healing. Our data suggest that Copine-III is a novel player in the regulation of ErbB2-dependent cancer cell motility. In primary breast tumors, high CPNE3 RNA levels significantly correlate with ERBB2 amplification. Moreover, in an in situ tissue microarray analysis, we detected differential protein expression of Copine-III in normal versus breast, prostate and ovarian tumors, suggesting a more general role for Copine-III in carcinogenesis.
Introduction
The ErbB2/Her-2/Neu receptor belongs to the type I receptor tyrosine kinase family also including EGFR, ErbB3 and ErbB4 (Schlessinger, 2000) . Alterations in EGFR or ErbB2 promoting constitutive receptor activation have been implicated in development of many human cancers. Patients whose tumors show ErbB receptor alterations tend to have an aggressive disease and poor prognosis (Slamon et al., 1987; Ross and Fletcher, 1998; Holbro and Hynes, 2004; Hynes and Lane, 2005) . Upon binding of EGF-related ligands to ErbBs, receptor homo-and heterodimers form, leading to kinase activation and phosphorylation of specific tyrosine residues in the cytoplasmic tail (Hazan et al., 1990; Hynes and Lane, 2005) . ErbB2 has no ligand, but is the favored dimerization partner of the other family members (Graus-Porta et al., 1997) . ErbB3, although able to bind ligands, has impaired kinase activity. ErbB2 is the preferred heterodimerization partner of ErbB3, thereby coupling ErbB2 to the phosphatidylinositol 3-kinase pathway (Holbro et al., 2003) . ErbB2, through activation of signaling pathways including Erk and phosphatidylinositol 3-kinase/Akt mediates numerous cellular processes important for tumorigenesis, including proliferation, survival and migration (Keely et al., 1997; Klemke et al., 1997; Schlessinger, 2000; Yarden and Sliwkowski, 2001; Citri and Yarden, 2006) .
The five major tyrosine phosphorylation sites, Tyr1023/1028, Tyr1139/1144, Tyr1196/1201, Tyr1222/ 1227 and Tyr1248/1253 (human/rat), and their role in ErbB2 signaling have been studied by various means. Tyr1028 couples to a pathway implicated in negative regulation of NeuT transforming potential, whereas the four other sites have a potentiating effect. Tyr1144, Tyr1201 and Tyr1227 signal through the Ras/Erk pathway by binding Grb2, Crk and Shc (Akiyama et al., 1991; Dankort et al., 1997 Dankort et al., , 2001 , which also binds Tyr1253 (Schulze et al., 2005) . The role of pTyr residues has also been examined in migration assays. In T47D breast tumor cells, Tyr1196 and Tyr1222 each have been linked to ErbB2-mediated cell migration through PLCg and Memo, respectively (Marone et al., 2004; Meira et al., 2009) .
We set out to identify novel binding proteins for Tyr1248 and to link them to an ErbB2-mediated phenotype. Using a pTyr1248 encompassing peptide in an affinity pull-down approach followed by relative quantification by mass spectrometry, we identified Copine-III, which belongs to a family of Ca 2 þ -dependent phospholipid-binding proteins first found in the ciliate protozoan Paramecium tetraurelia. Copines are conserved from plants to humans, where nine CPNE genes have been identified (CPNE 1-9) (Tomsig and Creutz, 2002) . All copines possess two N-terminal C2 domains (C2Ds) followed by a von Willebrand A-like or A domain. C2Ds were originally identified in conventional protein kinase C (PKC) isoforms and have been found in a growing number of eukaryotic proteins (Nalefski and Falke, 1996) . The copine A domain, although similar to the extracellular A domain of integrins, is cytoplasmic and thought to mediate protein-protein interactions (Tomsig and Creutz, 2002) .
Although widely expressed throughout the eukaryotes, indeed, most cells express multiple copines, relatively little is known about their specific roles. Interestingly, Copine-III was shown to be upregulated in tumor cells in response to ErbB2 overexpression (Gharbi et al., 2002; White et al., 2004) . We examined the role of Copine-III downstream of ErbB2 receptor signaling and show here that Copine-III is a Ca 2 þ -dependent, phospholipid-binding protein that interacts with activated ErbB2 at the plasma membrane (PM) of tumor cells. Moreover, we identified the focal adhesion (FA)-associated scaffold protein RACK1 (receptor of activated C kinase 1) as a Copine-III binding partner. Importantly, we show that Copine-III is required for ErbB2-dependent cell migration.
Results

Identification of Copine-III as an ErbB2 binding partner by quantitative mass spectrometry
To identify proteins that specifically bind to pTyr1248 of ErbB2, we used stable isotope labeling of amino acids in cell culture (SILAC) (Blagoev et al., 2003) in combination with an in vitro peptide affinity pull-down approach (Schulze and Mann, 2004) , followed by relative quantification by mass spectrometry (Figure 1a ). Endogenous amino acids in the T47D breast cancer cell line were substituted by their light (Lys0 and Arg0) and heavy (Lys6 and Arg10) forms. Extracts from both populations were subjected to an affinity pull down using peptides (Tyr and pTyr) encompassing Tyr1248 of the C-terminal tail of ErbB2. Bound proteins were eluted, subjected to SDS-polyacrylamide electrophoresis, digested with trypsin and identified by liquid chromatography-mass spectrometry/mass spectrometry (LC-MS/MS).
Over 100 proteins were identified in each individual pull-down experiment; however, only proteins identified by X2 peptides and with a Mascot protein score X20 were selected. For quantification, specific transitions for the light and heavy form of each peptide were measured over time using multiple reaction monitoring (MRM). The ratio of the peak area for the heavy form over that of the light form was calculated. The majority of the proteins yielded a quantification ratio of around 1, reflecting equal binding to the Tyr and the pTyr peptide ( Figure 1b) . A protein was considered as a specific binder if the mean a ratio of all its quantified peptides was X1.5. Copine-III (accession. number AAH07017) was quantified with ratio of 1.8 in three independent experiments (Figure 1c) .
The selective binding of Copine-III was confirmed using western blot analysis with a Copine-III-specific antibody. Tyr1248 and pTyr1248-containing peptides were incubated with T47D cell lysates and used as affinity reagents. Shc, which has been identified as a pTyr1248-binding protein (Dankort et al., 2001; Schulze et al., 2005) , was also examined as a control. These results confirmed the specific binding of Copine-III to the pTyr1248-containing peptide (Figure 1d ).
Copine-III is a Ca 2 þ -dependent, membrane-binding protein Copine-III belongs to a family of proteins, which have been shown to be Ca 2 þ -dependent, phospholipid binders (Creutz et al., 1998; Tomsig et al., 2003) . Copine-III is ubiquitously expressed in human tissues (HUGE database); however, essentially nothing is known about its role in normal or cancer tissue. It was shown that Copine-III mRNA and protein are upregulated in response to ErbB2 expression levels and activation . Peptide pull downs using HRG-stimulated T47D cell extracts were performed and the bound proteins (elution) were monitored by western blot. As a control for equal loading, fractions of the input cell lysate were also loaded on the gel (input). (Gharbi et al., 2002; White et al., 2004) . Therefore, we examined Copine-III in more detail using the breast cancer cell lines T47D, with moderate ErbB2 levels, and SKBr3, which has ERBB2 amplification and very high levels of the receptor (Lane et al., 2000) . The effect of Ca 2 þ on cellular location of Copine-III was first assessed by subcellular fractionation experiments. Cells were lysed in buffer containing CaCl 2 or EGTA and crudely fractionated into cytoplasmic (C) and membrane (M) fractions. In both cell lines, Copine-III was enriched in the membrane fraction in the presence of Ca 2 þ and shifted to the glyceraldehyde-3-phosphate dehydrogenase-containing cytoplasmic fraction after the addition of EGTA (Figure 2a) . These results show that Ca 2 þ is required for Copine-III localization to membranes. Calnexin, an integral membrane protein of the endoplasmic reticulum, was detected in the crude membrane fraction. Thus, we used immunofluorescence microscopy (IF) to see whether Copine-III bound to the endoplasmic reticulum or to the PM in response to Ca 2 þ , by treating the cells with the Ca 2 þ -ionophore ionomycin. Copine-III was detected using a monoclonal antibody directed against its C2B domain. The specificity of the antibody was verified using Copine-III knockdown (KD) cells (Supplementary Figure 1) .
Interestingly, for both cell lines, Copine-III was detected in the nucleus upon treatment with ionomycin. However, the role of Copine-III in the nucleus was not further pursued in this study. In control dimethyl sulfoxide-treated cells, Copine-III was found mainly in the cytoplasm; treatment with ionomycin caused its relocalization to the PM (Figure 2b) . In T47D cells, Copine-III staining was enriched at cell-cell adhesion membranes (Figure 2b , left), whereas in SKBr3 cells Copine-III localized to specific regions at the PM (Figure 2b, right) . Thus, Copine-III is a Ca 2 þ -dependent, membrane-binding protein.
Copine-III and ErbB2 colocalize and interact at the PM We explored the localization of Copine-III and ErbB2 in the breast cancer cell lines using IF. In control T47D cells, Copine-III was diffusely distributed throughout the cytoplasm. In response to HRG, Copine-III relocalized to the PM, where it colocalized with activated ErbB2 (Figure 3a) . In control SKBr3 cells, most of Copine-III was diffusely distributed throughout the cytoplasm; however, a portion also colocalized with the receptor at the PM. In SKBr3 cells, ErbB2 has high levels of pTyr, even in the absence of ligands. HRG treatment caused ErbB2 to distribute along the PM, and increased Copine-III at the membrane, where it colocalized with total ErbB2 (Figure 3b ) and pTyr1248-ErbB2 (Supplementary Figure 2) .
Next we used fluorescence resonance electron transfer (FRET) acceptor photobleaching (Kenworthy, 2001) to examine the interaction of Copine-III and ErbB2 in fixed, HRG-treated SKBr3 cells. Copine-III and ErbB2 were labeled with specific primary antibodies and with a donor (Alexa488) and acceptor (Cy3) fluorophore-conjugated secondary antibody, respectively. Acceptor photobleaching was performed and FRET efficiency was measured at three regions: (1) at the membrane where both proteins colocalize, (2) in the cytoplasm where there is no colocalization and (3) outside the cell to measure background fluorescence ( Figure 4a ). FRET efficiency (E) was calculated by comparing the Alexa488 intensities of region 1, after and before photobleaching of Cy3 (Figure 4b ). Donor intensities were corrected for background fluorescence (region 3) as well as bleaching due to imaging (region 2).
FRET efficiency was measured between ErbB2 and transferrin receptor (TR) and ErbB2 and Copine-III. ErbB2 colocalized with both TR and Copine-III at the PM; however, no FRET efficiency was measured between ErbB2 and TR (E ¼ 0.6 ± 1), showing that these receptors colocalize but do not interact (Figure 4b , left). Importantly, a significant FRET efficiency was found for ErbB2 and Copine-III (E ¼ 8.3 ± 1.3) (Figure 4b , middle). As a control, no FRET efficiency was measured for only Alexa488 labeling of Copine-III (Figure 4b , right). These results suggest that ErbB2 and Copine-III interact at the PM in HRG-stimulated SKBr3 cells. Copine-III interacts with the active ErbB2 receptor at the PM To test directly if Copine-III interacts with active ErbB2, we pretreated SKBr3 cells with the ErbB tyrosine kinase inhibitor AEE788 (Traxler et al., 2004) before stimulating with HRG. In tyrosine kinase inhibitor-treated cells there was a dramatic decrease in the pTyr content of ErbB2 as shown by immunoprecipitating the receptor and probing the immunoprecipitates (IPs) with a pTyr-specific antibody (Figure 5a , left). In addition, the activity of the Akt and Erk pathways was also reduced (Figure 5a, right) . IF revealed that the intense regions of ErbB2-membrane staining in control cells were lost in tyrosine kinase 
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Copine-III only As a control transferrin receptor (TR) was visualized with an Alexa488-labeled and ErbB2 with Cy3-labeled secondary antibody and FRET efficiency was measured after acceptor photobleaching (ErbB2/TR, left). As an experimental control, Copine-III only was visualized with an Alexa488-labeled secondary antibody and FRET efficiency was measured after photobleaching (Copine-III only, right).
inhibitor-treated cells and the receptor relocalized to specific intracellular regions (Figure 5b ). Strikingly, in AEE788-treated cells there was little or no Copine-III at the PM in comparison to control cells, where there was intense membrane staining. Taken together, these results show that Copine-III requires active ErbB2 signaling at the PM for its localization there. We examined complexes of Copine-III and ErbB2 using co-IP experiments. ErbB2 was found in IPs of Copine-III from lysates of T47D and SKBr3 cells (Figures 5c and e) . In control cells an association of ErbB2 and Copine-III was detected, reflecting autocrine receptor activity in T47D cells (Meira et al., 2009) and ErbB2 overexpression in SKBr3 cells (Lane et al., 2000) . In Copine-III IPs from lysates of HRG-treated cells, there was an increase in complexed, active pTyrcontaining ErbB2 (Figure 5c and e). Copine-III does not possess an SH2-or a phosphotyrosine-pTyr binding domain. Shc has both domains and has also been found associated with pTyr1248 (Dankort et al., 1997; Schulze et al., 2005) (Figure 1 ). Shc was detected in Copine-III IPs from lysates of T47D cells, and Shc levels increased in response to HRG (Figure 5d ). Together, these data provide evidence that Copine-III is found in complexes with ErbB2 and with Shc, the latter perhaps mediating Copine-III binding to the receptor.
Copine-III interacts with RACK1 and both proteins complex with ErbB2
To gain more insight into the role of Copine-III in ErbB2-mediated cellular signaling, we sought to identify Copine-III binding partners. For this, SKBr3 cells with incorporated light or heavy isotopes of lysine and arginine (SILAC) were transfected with an empty control vector or a Flag-tagged Copine-III, respectively. Copine-III and ErbB2-mediated migration C Heinrich et al
After stimulation with HRG, anti-Flag affinity purification was performed and Copine-III binding partners were identified by MRM (Figure 6a ). The analysis yielded several putative binding partners (Supplementary Table 1 ), one of these being RACK1 (Ron et al., 1994 ; Figure 6a ). In an independent experiment, we quantified the relative amounts of RACK1 in Copine-III IPs from SKBr3 lysates by MRM. We found a 1.5-fold enrichment of RACK1 in Copine-III IPs versus control IPs (data not shown), confirming the interaction. An examination of ErbB2 IPs from SKBr3 and T47D cells showed ErbB2 phosphorylation at Tyr1248 and complexed Copine-III, Shc and RACK1 (Figures 6b and c) .
Copine-III localizes to focal adhesions (FAs) and is required for ErbB2-dependent tumor cell migration The adaptor protein RACK1 acts as a scaffold in numerous signaling events including cell migration, where it has been shown to localize to nascent FAs (Cox et al., 2003) . Our finding that Copine-III interacts with RACK1 prompted us to examine whether Copine-III might also have a role in cell migration. First, we used IF to examine Copine-III localization.
Copine-III and phosphorylated focal adhesion kinase (pTyr397FAK) were both diffusely present in the cytoplasm of control T47D cells and on HRG treatment colocalized at the PM (Figure 7a ), suggesting that Copine-III is a FA-associated protein.
Next we examined the role of Copine-III in cell migration using a KD approach. Two pools of Copine-III KD cells and a pool expressing the control (LacZ) vector were generated in T47D cells. Copine-III KD was almost complete in pool 2, whereas it was approximately 50% in pool 1 (Figure 7b, inset) . The effect of Copine-III KD on migratory ability of T47D cells was examined using a wound-healing assay. Wound closure of control and Copine-III KD cultures left untreated or stimulated with HRG was monitored over 12 h (Figure 7b ). Basal migration of control cells was low and not affected by Copine-III KD. Importantly, compared to control cells, HRG-stimulated Copine-III KD cells were significantly impaired in their ability to migrate into the wound (Po0.005) (Figure 7b ). labeled with stable isotope labeling of amino acids in cell culture (SILAC) light (Lys0/Arg0) or heavy (Lys6/Arg10) isoforms) were transiently transfected with an empty vector or a vector-expressing Flag-Copine-III, respectively. Proteins were extracted and subjected to an affinity purification using anti-Flag columns. Specific binders to Flag-Copine-III were identified by liquid chromatography-mass spectrometry/mass spectrometry (LC-MS/MS) and quantified using multiple reaction monitoring (MRM). The protein ratios (heavy/ light) of all quantified proteins were plotted. The cutoff for specific binders was determined by assuming a normal distribution and setting the cutoff to ±2s from the mean. (b, c) Co-immunoprecipitate (IP) of Copine-III, Shc and RACK1 with ErbB2 in HRGstimulated cells. In IPs of ErbB2 from HRG-treated SKBr3 (b) and T47D (c) cells ErbB2 Tyr1248 phosphorylation was monitored with a specific antibody. In a further experiment ErbB2 co-IPs were monitored for Shc, Copine-III and RACK1 by western blotting. ErbB2 phosphorylation was monitored using a total phospho-tyrosine (pY) antibody. In parallel IgG IPs were probed as controls. Whole-cell extracts (WCE) are shown on the left.
Copine-III and ErbB2-mediated migration C Heinrich et al
The localization of Copine-III, pTyr397FAK and ErbB2 was also examined in wounded monolayers. In untreated cells none of these proteins strongly localized to the cell membrane (Figures 7c and d , phosphate-buffered saline (PBS)). In contrast, in HRG-treated cultures, Copine-III, pTyr397FAK and ErbB2 were each present in membrane protrusions at the edge of the wounded area. Moreover, a high degree of overlap between Copine-III and pTyr397FAK staining (Figure 7c ) and Copine-III and ErbB2 staining (Figure 7d ) was evident. In Copine-III KD cells, pTyr397FAK and ErbB2 were localized to membrane protrusions in response to HRG (data not shown), showing that these events are not dependent on Copine-III.
Src and FAK, two proteins with important roles in cell migration, were further analyzed. Src, but not FAK, was found in complex with ErbB2 after HRG stimulation (Figure 7e) .
A western analysis revealed that Src activity increased in control HRG-treated cells, as shown by the increase in pTyr418Src levels. In contrast, there was little or no increase in pTyr418Src levels in the two Copine-III KD pools (Figure 7f) . Moreover, the level of pTyr925FAK, a site that has been shown to require Src kinase activity to become phosphorylated (Brunton et al., 2005) , also increased in HRG-treated control cultures, whereas little or no increase was observed in Copine-III KD pools (Figure 7f ), attesting to the decrease in Src activity. In contrast to the effects on Src kinase activity, activation of the Akt and Erk pathways was similar in response to HRG treatment in the Copine-III KD cultures and the control cells (Figure 7f ). These findings imply that Copine-III might be a component of FAs that is required for Src activity and thus for regulating FA turnover and ErbB2-mediated migration in response to HRG.
Copine-III expression in human cancer
We examined Copine-III and ErbB2 expression levels in breast tumor cell lines and primary tumors. Copine-III was expressed to varying degrees in the breast cancer cells lines, with the highest levels in SKBr3 and BT474, both having ERBB2 amplification (Figure 8a ). These data correlate with previous publications showing Copine-III upregulation in response to ErbB2 overexpression (Gharbi et al., 2002; White et al., 2004) . We also examined Copine-III RNA expression in 49 primary breast tumors (Farmer et al., 2005) . Plotting log gene expression values of ERBB2 against expression values for CPNE3 revealed that high levels of CPNE3 were significantly correlated with ERBB2 amplification; 10 of 11 tumors which possess the ERBB2 amplicon also show high CPNE3 levels (Figure 8b) .
We also performed an analysis of Copine-III expression in different human tumors, initially examining data from published transcriptome studies (www.oncomine. org; Rhodes et al., 2004) . We found that CPNE3 expression increased significantly in metastatic prostate cancer in comparison to normal prostate and nonmetastatic tumors (data from  Figure 9a ). Moreover, in comparison to normal ovary, there were significantly higher levels of CPNE3 in ovarian endometrioid adenocarcinoma, the second most common type of ovarian cancer (data from Hendrix et al., 2006; Figure 9b ).
On the basis of these findings, we performed immunohistochemistry staining of Copine-III in breast, prostate and ovarian tissue microarrays. There was a tendency for Copine-III to be upregulated in the epithelial component of cancer tissue compared to normal tissue (Figure 9c ). Some Copine-III staining was evident in normal breast, whereas normal prostate and ovarian tissues have very low levels of Copine-III (Figure 9d ). Tumors of all three types showed higher Copine-III levels. These findings suggest that the upregulation trend revealed by the Oncomine analysis is retained at the protein level, implying a potential biological function of Copine-III in human cancer.
Discussion
ErbB2 has been shown to have a pivotal role in various types of human cancer. In breast cancer, ErbB2 over- (KD1 and KD2) . A control lacZ pool was also prepared. Expression levels of Copine-III in the KD1 and KD2 and the lacZ pools is shown; glyceraldehyde-3-phosphate dehydrogenase is the loading control (insert). T47D cells were grown to confluency, starved in Dulbecco's modified Eagle's medium for 8 h, then stimulated with 1 nM HRG and subsequently scratched. Cell migration into the wound was monitored for 12 h in 4-6 regions of the scratch. The recovered area of the wound is shown by the mean ± s.e.m. *Po0.005. (c, d) Localization of Copine-III and pTyr397FAK (c) and Copine-III and ErbB2 (d) in migrating T47D cells. Cells were grown to confluency, starved overnight, then stimulated with 5 nM HRG, scratched and allowed to migrate for 1.5 h before they were fixed and stained. Copine-III, pTyr397FAK and ErbB2 were visualized by immunofluorescence microscopy (IF) using their respective antibodies. The direction of migration into the wound is indicated by the arrow. Merged images in the bottom panel include Hoechst staining for the nucleus in blue (scale bar: 10 mm). Insets show 2 Â zooms of boxed regions focusing on the leading edge of the migrating monolayer. (e) Co-IP of Src with ErbB2 in HRG-stimulated T47D cells. IPs of ErbB2 from HRG-treated T47D cells were monitored for Src and pY418 Src by western blotting. ErbB2 was monitored using a total ErbB2 antibody and its phosphorylation was analyzed using a pTyr1248 specific antibody. In parallel IgG IPs were probed as controls. Whole-cell extracts (WCE) are shown on the left. (f) The two pools of Copine-III KD T47D cells, the control lacZ pool and the parental cells were treated or not with HRG for 20 min. Cell lysates were prepared and western blots were probed for the level of FAK, pTyr925FAK, Src, pTyr418Src, Akt, pAKT, Erk1/2, pErk1/2 and Copine-III.
Copine-III and ErbB2-mediated migration C Heinrich et al expression correlates with aggressive disease and a metastatic phenotype (Hynes and Lane, 2005) . In search of novel ErbB2 effector proteins, we identified Copine-III by its ability to specifically bind an ErbB2 pTyr1248-containing peptide. Our results show that Copine-III interacts with ErbB2 at the PM of breast tumor cells in response to HRG treatment. Moreover, we show that Copine-III binds the FA-associated protein RACK1 and is also present in FAs in cells with active ErbB2. Importantly, KD of Copine-III in T47D breast tumor cells causes a decrease in HRGinduced migration. Our results suggest that Copine-III is a novel ErbB2-interacting protein that might link ErbB2 to FAs, thereby contributing to HRG-induced cell motility.
Copines are a conserved family of ubiquitously expressed proteins found in many eukaryotic organisms (Tomsig and Creutz, 2002) properties and A domains bind proteins (Tomsig et al., 2003) . Copine family members from various organisms have been shown to bind membranes (Hua et al., 2001; Church and Lambie, 2003; Gottschalk et al., 2005) . Bioinformatic analysis showed that aspartate residues required for Ca 2 þ -binding are conserved in both Copine-III C2Ds. In addition, between the C2D-B and the A domain of Copine-III there is a Lys-rich cluster, which, in PKCs, has been shown to bind phosphatidylinositol(4,5)P2 thereby strengthening membrane affinity (Guerrero-Valero et al., 2007) . Using IF we show that Copine-III and ErbB2 colocalize to the PM after HRG stimulation. Moreover, in FRET acceptor photobleaching experiments, we measured a FRET efficiency of 8±3 between ErbB2 and Copine-III, which agrees well with the FRET efficiency of 14 ± 3 between ErbB2 receptors (Nagy et al., 1998) . Taken together, our analysis of Copine-III suggests that it is a Ca 2 þ -dependent membrane-binding copine that responds to ErbB2 activation and localizes to the PM in proximity to the receptor.
How does Copine-III interact with ErbB2? C2Ds have been classified as Type I and Type II (Nalefski and Falke, 1996) and the Type II C2D of PKCd has been shown to directly bind specific pTyr-containing peptides (Benes et al., 2005) . However, we consider it unlikely that Copine-III directly binds ErbB2 because a bioinformatic analysis suggested that Copine-III's C2Ds are both likely to be Type I. Moreover, the residues in PKCd that have been shown to be essential for pTyr binding are not conserved in Copine-III. We favor the hypothesis that Shc, which possesses both an SH2 and a phosphotyrosine-binding domain, mediates Copine-III's interaction with ErbB2. Indeed, complexed Shc was identified in Copine-III co-IPs (Figure 5d ). Although copines have been linked to other membrane receptors, including the nicotinic acetylcholine receptor in Caenorhabditis elegans and the tumor necrosis factor a receptor in human embryonic kidney (Tomsig et al., 2004; Gottschalk et al., 2005) , this is the first description of a copine interaction with ErbB2 or any other receptor tyrosine kinase.
Copine A domains have been shown to bind various proteins selectively (Tomsig et al., 2003) , which suggests that different copines respond to Ca 2 þ signals by transporting selectively bound proteins to phospholipid-containing membranes, where they influence activity of signaling pathways. Using mass spectrometry, we identified seven Copine-III interacting proteins, RACK1 ( Figure 6 ) and six other cytoplasmic and nuclear proteins (Supplementary Table 1 ). This is interesting as we also observed enhanced Copine-III nuclear (Farmer et al., 2005) . Log expression of CPNE3 is plotted on the y axis and ERBB2 log expression values on the x axis. Axes are plotted through the median expression levels of CPNE3 and ERBB2, respectively. The different subtypes of the analyzed breast tumors are denoted: basal ( ), apocrine ( ) and luminal ( ). ERBB2-amplified tumors are highlighted with circles.
Copine-III and ErbB2-mediated migration C Heinrich et al staining following Ca 2 þ stimulation or HRG treatment (Figures 2b and 3 ) and Copine-III nuclear staining was observed on breast and prostate tissue microarrays (Figure 9d, arrows) . However, this was not pursued further in our studies, which were focused on the Copine-III binding partner RACK1.
The adaptor protein RACK1 acts as a scaffold in numerous signaling events including cell migration, where it has been shown to localize to nascent FAs (Cox et al., 2003) . RACK1 was recently shown to associate with and be required for FAK activation (Kiely et al., 2009) . We provide evidence that Copine-III binds RACK1 and colocalizes with pFAK at FAs in the migrating front of breast cancer cells. Moreover, in Copine-III KD cells we observe decreased Src activity and decreased FAK phosphorylation at the Src site (pY925). Phosphorylation of Tyr925FAK by Src is required for proper FA turnover and cell migration (Brunton et al., 2005) . A RACK1-Src association has been described (Miller et al., 2004) . Thus, we postulate that Copine-III is a ErbB2-and Ca 2 þ -dependent membrane-binding protein that functions at FAs, where it contributes to Src activity and tumor cell migration. The exact mechanism by which Copine-III influences cell migration still remains to be elucidated in future studies. Because other cellular readouts, such as proliferation and anchorage-independent growth, were unaltered in Copine-III KD T47D cells, Copine-III's influence in response to HRG appears to be specific to migration (Supplementary Figure 3) .
By performing pull-down assays with ErbB2 pTyrcontaining peptides we have identified multiple proteins with roles in migration (Marone et al., 2004) . PLCg1 and Memo were shown to interact with pTyr1996 and pTyr1222, respectively, and cells with KD of either protein were impaired in HRG-induced directional migration (Meira et al., 2009) . Using a KD approach, we show here that Copine-III is also required for HRGinduced T47D cell migration. It is tempting to speculate that in cells with low Copine-III, ErbB2 loses its ability to couple to proteins and pathways involved in motility. Considering these and other proteins that interact with ErbB2, we propose the following model: in response to ligand activation, ErbB2 binds and activates PLCg1 (Meira et al., 2009) , which causes an increase in diacylglycerol levels and initiates Ca 2 þ influx from the endoplasmic reticulum and through store-operated channels into the cytoplasm (Patterson et al., 2005; Kheifets and Mochly-Rosen, 2007) . Interestingly, specific residues that have been mapped in the C2D of PKCa as being essential for RACK1 binding (McCahill et al., 2002) are conserved in Copine-III C2D-B. Therefore, it might be possible that RACK1, which is thought to direct PKCs to specific membrane locations (Kheifets and MochlyRosen, 2007) , might also direct Copine-III to the PM in proximity to ErbB2. This enables Copine-III to interact with the receptor and influence Src activity and cell migration (Figure 10) .
In primary human tumors, there was some evidence for a functional relationship between Copine-III and ErbB2, because Copine-III mRNA and protein levels were shown to correlate with ErbB2 expression (Gharbi et al., 2002; White et al., 2004) . We have extended these studies by examining a panel of 49 breast tumors (Farmer et al., 2005) and showing that there is a significant correlation between CPNE3 RNA levels, and ERBB2 gene amplification and expression. Furthermore, data mining (Oncomine) and data from our own tissue microarrays provide evidence that Copine-III levels are increased in prostate and ovarian tumors. Taken together, these results suggest that Copine-III function might be important in multiple cancer types. Our results implicate Copine-III as an important player in ErbB2-mediated cancer cell motility making Copine-III an interesting target in ErbB2-mediated cancers.
Materials and methods
Mass spectrometry and quantification
The Coomassie-stained bands were processed by reduction and alkylation of the cysteines followed by tryptic digestion. Peptides were analyzed by nano-HPLC (Agilent 1100 nanoLC system; Agilent Technologies, Santa Clara, CA, USA) coupled to a 4000QTRAP mass spectrometer (Applied Biosystems, Figure 10 Hypothetical model for the role of Copine-III in ErbB2-dependent cell migration. On stimulation of ErbB2/ErbB3 heterodimers with HRG (1), PLCg1 binds pTyr1996 of ErbB2 and, once activated, cleaves PIP 2 into diacylglycerol and IP 3 (2), which binds IP 3 R (3) leading to the release of Ca 2 þ from intracellular stores and through store-operated channels (4). Ca 2 þ influx allows Copine-III to relocate to the nucleus or the plasma membrane (5). The elucidation of a putative role for Copine-III in the nucleus awaits further investigation. At the plasma membrane (PM), RACK1 directs it to a specific membrane location in proximity to ErbB2. It is possible that Copine-III interacts with RACK1 through a conserved motif in the C2 domain (C2D) (McCahill et al., 2002) . Copine-III associates with pTyr1248, very likely through Shc, and influences Src activation (6), thereby influencing ErbB2-induced cell migration (7). We have seen a direct interaction of Src with ErbB2 in our experiments, which we have shown here. We have drawn a direct Shc-Copine-III interaction; however, as indicated by the dots, it is possible that another protein mediates the interaction.
